

AMENDED CLAIMS

1. Use of a cell, which does not naturally express CD154, wherein said cell is transfected with DNA encoding CD154, for the manufacture of a tissue composition for use in tissue engineering.
2. Use according to Claim 1 wherein said cell is transfected with genomic DNA.
3. Use according to Claim 1 wherein said cell is transfected with cDNA.
4. Use according to any of claims 1 - 3 wherein said cell is of mammalian origin.
5. Use according to claim 4 wherein said cell is of human origin.
6. Use according to any of claims 1 - 5 wherein said cell is selected from the following cell types: fibroblast; keratinocyte; osteoblast; chondrocyte; neurone; myocyte; hepatocyte; splenocyte; pancreatic  $\beta$  cells.
7. Use of a cell according to any of claims 1-6 for use in the manufacture of a medicament for use in therapeutic tissue engineering.
8. Use of a cell according to any of claims 1-6 for use in the manufacture of a medicament for use in cosmetic tissue engineering.
9. Use of a vector which includes a nucleic acid molecule which encodes CD154, wherein said vector is adapted for recombinant expression of CD154, for the manufacture of a medicament for use in tissue engineering.
10. Use of a vector according to claim 9 wherein said vector comprises a cell/tissue specific promoter sequence.
11. Use of a vector according to claim 10 wherein said promoter is cell/tissue specific for one of the following tissue types: neuronal; smooth muscle; striated

25-JUL-2001 00:23 FROM HARRISON GUDARD & CO. 10 300430523330110 F.03/00  
20031774.082602

muscle; cardiac muscle; bone; cartilage; liver; kidney; respiratory epithelium; endothelium; haematopoietic cells; spleen; pancreas; skin; stomach; intestine; oesophagus; blood vessels.

12. An *in vitro* method to transfect a selected cell/tissue wherein said cell/tissue does not naturally express CD154, comprising:

- i) incubating cells/tissues under conditions conducive to the introduction and maintenance of a vector according to any of claims 9-11;
- ii) exposing said cells to an agent at a concentration sufficient such that at least those cells/tissues including said vector are selected for and optionally,
- iii) culturing said cells/tissues containing vector; and, optionally further still,
- iv) storing said cell culture prior to use.

13. A method according to claim 12 wherein said cell/tissue is a mammalian cell/tissue.

14. A method according to claim 12 or 13 wherein said mammalian cell/tissue is of human origin.

15. A method according to any of claims 12-14 wherein said transfection is transient.

16. An organ comprising at least one cell, wherein said cell does not naturally express CD154, which cell has been transfected with a vector according to any of Claims 9-11.

17. A method of treatment comprising:

- i. providing at least one cell wherein said cell does not naturally express CD154, which cell is transfected with a nucleic acid molecule encoding CD154; and
- ii. administering said cell to a patient to be treated.

18. A therapeutic vehicle comprising a cell according to any of claims 1-8.
19. A therapeutic vehicle according to claim 18 wherein said therapeutic vehicle is selected from: a prosthesis; implant; matrix; stent; gauze; bandage; plaster; biodegradable matrix; polymeric film.
20. A cosmetic vehicle comprising a cell according to any of claims 1-8.